» Articles » PMID: 11522632

Carbonic Anhydrase (CA IX) Expression, a Potential New Intrinsic Marker of Hypoxia: Correlations with Tumor Oxygen Measurements and Prognosis in Locally Advanced Carcinoma of the Cervix

Overview
Journal Cancer Res
Specialty Oncology
Date 2001 Aug 28
PMID 11522632
Citations 158
Authors
Affiliations
Soon will be listed here.
Abstract

There is increasing evidence that hypoxia-regulated gene expression influences tumor aggressiveness, contributing to the poorer outcome of patients with hypoxic tumors. The role of the transcriptional complex hypoxia-inducible factor-1 as an important mediator of hypoxia-regulated gene expression is one of the best documented pathways. Recently, it has emerged that certain tumor-associated carbonic anhydrases (CAs) can be added to the list of known hypoxia-inducible factor-responsive genes. Here we show that the immunohistochemical expression of the tumor-associated CA IX is correlated with the level of hypoxia in human cervical tumors. We performed a prospective study in 68 patients where needle electrodes were used to make direct measurements of tumor oxygenation levels. CA IX expression was evaluated immunohistochemically in pretreatment tumor biopsies. There was a significant positive correlation between the level of tumor hypoxia (HP5) and the extent of CA IX expression. A retrospective study of 130 squamous cell cervical carcinomas demonstrated that a semiquantitative immunohistochemical analysis of CA IX expression in tumor biopsies is a significant and independent prognostic indicator of overall survival and metastasis-free survival after radiation therapy. These studies provide clinical evidence that CA IX expression is up-regulated in hypoxic human cervical tumors and is associated with a poor prognosis. CA IX may act as an intrinsic marker of tumor hypoxia and poor outcome after radiation therapy. The level of CA IX expression may be used to aid in the selection of patients who would benefit most from hypoxia-modification therapies or bio-reductive drugs.

Citing Articles

Is there a role for [F]-FMISO PET to guide dose adaptive radiotherapy in head and neck cancer? A review of the literature.

Sambasivan K, Barrington S, Connor S, Witney T, Blower P, Urbano T Clin Transl Imaging. 2024; 12(2):137-155.

PMID: 39286295 PMC: 7616449. DOI: 10.1007/s40336-023-00607-y.


CA9, CYFIP2 and LGALS3BP-A Novel Biomarker Panel to Aid Prognostication in Glioma.

Hudson A, Cho A, Colvin E, Hayes S, Wheeler H, Howell V Cancers (Basel). 2024; 16(5).

PMID: 38473425 PMC: 10931055. DOI: 10.3390/cancers16051069.


Hypoxia-induced ZEB1 promotes cervical cancer immune evasion by strengthening the CD47-SIRPα axis.

Chen X, Guo C, Wang Z, Yang Y, Pan Y, Liang J Cell Commun Signal. 2024; 22(1):15.

PMID: 38183060 PMC: 10768116. DOI: 10.1186/s12964-023-01450-4.


Co-vulnerabilities of inhibiting carbonic anhydrase IX in ferroptosis-mediated tumor cell death.

McDonald P, Dedhar S Front Mol Biosci. 2023; 10:1327310.

PMID: 38099193 PMC: 10720035. DOI: 10.3389/fmolb.2023.1327310.


Diagnostic, Prognostic, and Therapeutic Role for Angiogenesis Markers in Head and Neck Squamous Cell Carcinoma: A Narrative Review.

Alessandrini L, Astolfi L, Daloiso A, Sbaraglia M, Mondello T, Zanoletti E Int J Mol Sci. 2023; 24(13).

PMID: 37445908 PMC: 10341715. DOI: 10.3390/ijms241310733.